INmuneBIO
La Jolla
About INmuneBIO
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $144.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: nasdaq:INMB
- Website: inmunebio.com
- Phone: (858) 964 3720
Industries & Categories
Biotechnology, Commercial, Industrial, Medical
Social Profiles
Canonical: https://fsome.com/organization/inmunebio-156462 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.